KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palvella Therapeutics (PVLA) Short-term Investments (2017 - 2026)

Palvella Therapeutics has reported Short-term Investments over the past 5 years, most recently at $20.5 million for Q4 2022.

  • Quarterly Short-term Investments changed N/A to $20.5 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $20.5 million through Dec 2022, changed N/A year-over-year, with the annual reading at $20.5 million for FY2022, N/A changed from the prior year.
  • Short-term Investments was $20.5 million for Q4 2022 at Palvella Therapeutics, down from $21.4 million in the prior quarter.
  • Over five years, Short-term Investments peaked at $100.4 million in Q2 2018 and troughed at $15.8 million in Q3 2020.
  • The 4-year median for Short-term Investments is $40.2 million (2019), against an average of $40.7 million.
  • Year-over-year, Short-term Investments surged 53.2% in 2018 and then plummeted 60.8% in 2020.
  • A 4-year view of Short-term Investments shows it stood at $53.2 million in 2018, then decreased by 21.31% to $41.9 million in 2019, then tumbled by 62.41% to $15.8 million in 2020, then surged by 30.37% to $20.5 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Short-term Investments are $20.5 million (Q4 2022), $21.4 million (Q3 2022), and $26.7 million (Q2 2022).